Sagimet plans to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination of denifanstat and resmetirom in the second half of 2025, with an anticipated data readout in the first half of 2026. Sagimet initiated a Phase 1 clinical trial of TVB-3567, for development of an acne indication. Contingent on discussions with regulatory authorities and the outcome of the Phase 1 trial, the Company anticipates starting the Phase 2 program in moderate to severe acne patients in 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences reports Q2 EPS (32c), consensus (50c)
- Sagimet Biosciences initiated with an Outperform at Wedbush
- Eli Lilly downgraded, Lyft upgraded: Wall Street’s top analyst calls
- Promising Prospects for Sagimet Biosciences: Buy Rating Backed by Innovative FASN Inhibitor Platform and Clinical Advancements
- Sagimet Biosciences assumed with a Buy at H.C. Wainwright